[Role of monoclonal anti-IgE antibodies (rhu-MAb) in the treatment of allergic bronchial asthma].
The key role in the mechanism of immune response to allergenic exposure in bronchial asthma is played by immunoglobulins E (IgE), which bind to specific Fce receptors on mast cells, basophils, B-lymphocytes and eosinophils. The specific recombinant human monoclonal antibodies (rhu-MAb) directed against free IgE are a new promising therapeutic remedy for symptoms of allergic asthma. In this article the review of clinical studies concerning the usefulness of rhu-MAb in treatment of bronchial asthma is presented.